Navigation Links
Heptares to Present at BIO-Europe 2012
Date:11/8/2012

WELWYN GARDEN CITY, England and BOSTON, November 8, 2012 /PRNewswire/ --



Heptares Therapeutics, the leading GPCR drug discovery company, announces that its Chief Executive Officer, Malcolm Weir, will present the Company at BIO-Europe 2012, the international partnering conference, which takes place at the CCH Congress Center, Hamburg, Germany (12-14 November 2012).

Dr Weir's presentation will be at 2:15pm (CET)on Tuesday 13 November in Room B1, Level 1.

About Heptares Therapeutics

Heptares discovers and develops new medicines targeting GPCRs (Gprotein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases.  Our pharmaceutical partners include Shire, AstraZeneca, MedImmune and Takeda, and we have raised $40M from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures.

Heptares is pioneering the application of structure-based drug design to the GPCR super-family of targets and is focused on creating molecules that modulate high-value, yet historically undruggable or challenging, GPCRs.  Our platform incorporates proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time.

Using this approach, we have generated a broad pipeline of drug candidates for the treatment of serious disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression, chronic insomnia, addiction disorders, migraine and diabetes.  For more information about Heptares, please visit http://www.heptares.com.


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Heptares Solves First Family B GPCR Structure
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
4. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
5. Organovo To Present At Lazard Healthcare Conference
6. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
7. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
8. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
9. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
11. PAREXEL International to Present at Morningstar Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):